针对结构性心脏病进行过导管干预的患者的抗血栓治疗
Paolo Calabrò1,2, Felice Gragnano1,2, Giampaolo Niccoli3,4,5
1Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (P.C., F.G., E.M., A.C.).
Circulation
|October 18, 2021
概括
通过导管进行心脏结构干预的平衡抗血栓治疗是复杂的. 本综述强调了预防血栓的证据,同时尽量减少这些手术中的出血风险.
科学领域:
- 心脏病学
- 干预心脏病学
- 心血管医学
背景情况:
- 基于器件的跨导管干预越来越多地用于结构性心脏病.
- 这种手术包括大动脉植入,中心/三门修复/植入,左心房尾闭塞,孔关闭.
- 这些干预措施需要抗血栓治疗来预防血栓栓塞事件.
研究的目的:
- 审查基于设备的跨导管干预的抗血栓治疗现有证据.
- 强调平衡血栓和出血风险的挑战.
- 突出需要根据特定程序定制的抗血栓治疗方案.
主要方法:
- 对当代证据进行系统审查.
- 在各种跨导管结构干预中分析抗血栓策略.
- 对影响治疗的临床指示和程序方面的讨论.
主要成果:
- 抗血栓治疗至关重要,但也可能导致出血.
- 最佳的抗血栓治疗方案尚不清楚,并且取决于程序.
- 个性化的方法对于控制血栓和出血风险至关重要.
结论:
- 有证据支持基于器件的跨导管干预用于结构性心脏病.
- 仔细考虑抗血栓治疗对于优化患者的结果至关重要.
- 需要量身定制的抗血栓策略来平衡疗效和安全性.
相关概念视频
Venous Thrombosis III: Interprofessional Care
58
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
58
Coronary Artery Disease V: Interprofessional Care
68
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
68
Acute Coronary Syndrome IV: Interprofessional Care
49
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
49
Peripheral Artery Disease III: Interprofessional Care
56
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
56
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
750
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
750
Atherosclerosis III: Management
63
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63


